Prostatilen/Vitaprost [Prostate Peptides]

Formulation and packaging

Lyophilisate for solution for injection in a form of powder, in ampoules.

One ampoule contains the active water-soluble peptide content of the bull prostate tissue extract – 5 mg.

Rectal suppositories. One suppository contains:

the active water-soluble peptide content of the bull prostate tissue extract – 30 mg, and inactive ingredients (dimethyl sulfoxide and polyethylene glycol in the amount essential to make a 2.8 g suppository).

Enteric coated tablets. One tablet contains:

Active ingredient: bull prostate tissue extract (powder) 100 mg, with the active peptide content of 20 mg.

Inactive ingredients: sucrose, lactose, calcium stearate, crospovidone and microcrystalline cellulose

Application and dosage

Dosage for the injections is 5-10 mg once a day. Dissolve the lyophilisate in 1-2 ml of 0.9% sodium chloride solution or 0.25-0.5% novocaine solution. The duration of treatment course is 5-10 days. If necessary, the treatment course can be repeated after 1-6 months.

Suppositories are to be administered rectally. The dosage is 1 suppository 1-2 times a day (in the morning and in the evening). It is recommended to administer a suppository after emptying one’s bowels and having hygiene procedures. Apply a small amount of water to the suppository. Insert the suppository into the rectum. It is recommended to sit or lie with one’s legs closed for 30-40 minutes. The duration of treatment course is 5-10 days.

Tablets to be administered orally, 1 tablet 2 times a day. Duration of treatment is not less than 30 days in case of benign prostatic hyperplasia or not less than 10 days for chronic abacterial prostatitis.

Side effects

Allergic response.

Counterindications

Hypersensitivity to the components of the drug.

Overdose

No cases of overdose recorded.

Drug interaction

Prostatilen is compatible with antibacterial medications used in treating prostatitis.

Storage conditions

Store at a dark place. Keep out of the reach of children. Storage temperature for is not higher than 20°C for lyophilisate (or tablets) and 8-15°C for suppositories. Shelf life is 3 years.

Manufacturer

CJSC Cytomed St Petersburg, Russia

JSC Nizhpharm. Nizhny Novgorod, Russia (Tablets)

You can read the full instruction here

Prostatilen/Vitaprost is a medicine of animal origin aimed at treating prostate diseases. It has anti-inflammatory and prostatotropic effects. It helps treat edema, reduce the amount of leukocytes in the prostate gland, stabilize the secretion in epithelial cells and stimulate the muscle tone in the bladder. It also improves the blood supply in the prostate gland by reducing blood clotting and prevents the development of thrombosis

The research also shows that Prostatilen/Vitaprost can be used as part of complex therapy for treating male infertility, erectile dysfunction and acute cystitis.

Both drugs have the same active ingredient, but Prostatilen is used as suppositories or injections, while Vitaprost can be taken orally.

The drug’s main ingredient is the bull prostate tissue extract. It is most effective in:

  • reducing the inflammation;
  • improving blood circulation, which helps the prostate gland receive more oxygen;
  • improving sexual performance and semen quality;
  • stimulating the immune system;
  • strengthening the muscles of the bladder and urethra.
  • Indications

  • chronic abacterial prostatitis;
  • before and after prostate surgery;
  • benign prostatic hyperplasia.
    1. Kamalov et al (2006) Use of oral vitaprost in the treatment of chronic abacterial prostatitis https://www.ncbi.nlm.nih.gov/pubmed/17444152
    2. Mazo et al (2007) Efficacy and safety of a new dosage form of vitaprost (tablets coated with intestinally soluble cover) in patients with prostatic adenoma https://www.ncbi.nlm.nih.gov/pubmed/18649662
    3. Kamalov et al (2007) Vitaprost forte in the therapy of patients with prostatic adenoma https://www.ncbi.nlm.nih.gov/pubmed/17722619
    4. V Tkachuk, I Tkachuk (2008) Vitaprost forte efficacy in patients with prostatic adenoma https://www.ncbi.nlm.nih.gov/pubmed/19058362
    5. Miller et al (2008) Efficacy of vitaprost forte in patients with prostatic adenoma https://www.ncbi.nlm.nih.gov/pubmed/19069497
    6. Lopatkin et al (2009) Vitaprost plus in the treatment of chronic bacterial prostatitis https://www.ncbi.nlm.nih.gov/pubmed/19670818
    7. M Sitdykova, A Zubkov (2009) Efficacy of vitaprost forte in the treatment of prostatic adenoma https://www.ncbi.nlm.nih.gov/pubmed/20169719
    8. Iakovets et al (2011) Experience in vitaprost treatment of patients with chronic abacterial prostatitis and prostatic adenoma after prostatic arteries embolism https://www.ncbi.nlm.nih.gov/pubmed/22279784
    9. M Davidov (2011) Treatment of prostatic adenoma with concomitant chronic bacterial prostatitis https://www.ncbi.nlm.nih.gov/pubmed/21500490
    10. D Shafranov, A Mariupol'skiĭ (2011) Vitaprost-forte in the treatment of patients with prostatic adenoma https://www.ncbi.nlm.nih.gov/pubmed/22448483
    11. Neĭmark et al (2013) The use of drug vitaprost forte in patients with benign prostate hyperplasia https://www.ncbi.nlm.nih.gov/pubmed/23662497
    12. D Ergakov, A Martov (2013) Application of rectal suppository vitaprost plus before and after transurethral resection of the prostate https://www.ncbi.nlm.nih.gov/pubmed/23789370
    13. Demidko et al (2014) The use of vitaprost in the treatment of patients with prostate diseases https://www.ncbi.nlm.nih.gov/pubmed/24772777
    14. D Ergakov, A Martov (2015) Use of Vitaprost (tablets and rectal suppositories) for patients rehabilitation after invasive diagnostic urological interventions https://www.ncbi.nlm.nih.gov/pubmed/28247675
    15. I Korneev (2017) Russian experience with Vitaprost Forte suppositories in patients with lower urinary tract symptoms and benign prostatic hyperplasia: comparative analysis of studies https://www.ncbi.nlm.nih.gov/pubmed/28845952
    16. I Kuzmin (2019) Vitaprost Forte in the treament of patients with benign prostatic hyperplasia: pathogenetic basics and clinical results https://www.ncbi.nlm.nih.gov/pubmed/31535821


    Type: Unknown Type




    CUSTOMERS WHO BOUGHT THIS PRODUCT ALSO BOUGHT